Get started with Myriad's Prenatal Screening

Request more information about how Myriad’s prenatal screening options can benefit your patients.

Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time by using the unsubscribe link or instructions in any email communications we send. For further information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

Hidden Fields

Hidden test fields

Myriad Genetics’ Prenatal Screens

Guide every parent-to-be with genetic insights

Help patients of every background and BMI manage their pregnancy with screenings that offer the industry’s lowest failure rate1.

Myriad Genetics Prenatal Screens

Guide every parent-to-be with
genetic insights

Help patients of every background and BMI manage their pregnancy with screenings that offer the industry’s lowest failure rate.1

Are you an expecting or future parent? For expecting parentsFor those planning a family

Your partner in helping
hopeful parents

Your patients depend on you to guide them through all the screening options to manage their future or current pregnancy. The Foresight® Carrier Screen helps identify carriers of inherited health conditions that might be passed on to a child, while the Prequel® Prenatal Screen helps you gather more insight into the chromosome health of a current pregnancy and baby.

Guide patients to make well-informed decisions about:

  • Pursuing diagnostic testing
  • Consulting with specialists
  • Planning for pregnancy and delivery
  • Understanding alternative family-building options
plays How Myriad's prenatal screening can benefit your patients videolightbox

Learn how Myriad’s prenatal screening can benefit your patients.

We help you care for everybody

As the pioneer of expanded carrier screening and fetal fraction amplification technology, only Myriad has addressed these factors in inequity in prenatal screening. Our carrier screen and non-invasive prenatal screen are carefully designed to provide reliable and personalized results for every ancestry and BMI.

ForeSight Text Kit

Foresight® Carrier Screen

The best detection rate for parents of every ancestry

Carrier screening can identify couples who are at risk of passing inherited disorders to their children. Foresight elevates quality of care by enabling carrier screening for all patients, regardless of family history or ethnicity.

Identifies at-risk couples

Foresight detects 1 in 22 couples at-risk for passing serious and actionable conditions to their children — the highest published detection rate in the industry.2

>99% detection rate for the majority of genes

Be confident in both positive and negative results with >99% detection rates, regardless of ethnicity, for most of the genes in the panel.3

Clear results with pre- and post-screen support

We provide clear, user-friendly results as well as access to board-certified genetic counselors for patient education pre-and post-test.

ForeSight Text Kit

Foresight Patient Story:

Meet the Pantier Family

After screening with Foresight, Ashley and her husband discovered that they are both carriers of spinal muscular atrophy, also known as SMA. Knowing the Pantiers’ carrier status allowed physicians to diagnose their children faster and intervene quickly with time-sensitive treatment.

Prequel Text Kit

Prequel® Prenatal Screen with AMPLIFY Technology

Early insights into a baby’s development

As early as week 10, Prequel uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for a chromosome abnormality leading to conditions such as Down, Edwards, or Patau Syndromes. These results give your patients more time and information to plan and prepare.

AMPLIFY Technology

Prequel is the only NIPS with revolutionary AMPLIFY technology that increases fetal fraction for everybody, including patients with high BMI.1

Answers for patients of all BMIs

With the lowest proven failure rate of 0.1%, Prequel provides reliable and individualized insights for 99.9% of all patients of any BMI.4,5

Individualized results and support

Results that deliver clarity of patients’ true risk with individualized positive-predictive-values (PPV) and residual-risk estimates to help inform next steps.

Prequel Text Kit

Myriad CompleteTM

Your partner in patient care

With Myriad Complete, we support you and your patients throughout the genetic screening process:

    • Pre-screen education
    • Transparent pricing and billing support
    • Clear results reporting
    • Post-screen education

These solutions allow for seamless integration of Myriad Genetics’ prenatal screens into your clinical care routines to help patients better understand and benefit from their results.

The Myriad Genetics affordability commitment

Making genetic insights affordable for everybody

We’re committed to making prenatal genetic screening accessible for all patients who can benefit. Our financial assistance program takes into account each patient’s ability to pay, working with them directly to find the best option.

$0 out-of-pocket
  • Broad in-network status with health plans
  • 60% of patients qualify for financial assistance and payment plans
  • Personalized cost estimates ($150 is the average out-of-pocket cost)


  1. Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genet Med 23, 443–450 (2021).
  2. Hogan, et al. Clin Chem 2018; doi:10.1373/clinchem.2018.286823.
  3. Foresight® Residual Risk Table.
  4. Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenat Diagn. 2020;40(3):333-341. doi:10.1002/pd.5603.
  5. Hancock S, Ben-Shachar R, Adusei C, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020;56(3):422-430. doi:10.1002/uog.21904.